Application Information

This drug has been submitted to the FDA under the reference 022511/001.

Names and composition

"VIMOVO" is the commercial name of a drug composed of ESOMEPRAZOLE MAGNESIUM and NAPROXEN.

Forms

ApplId/ProductId Drug name Active ingredient Form Strenght
022511/001 VIMOVO ESOMEPRAZOLE MAGNESIUM; NAPROXEN TABLET, DELAYED RELEASE/ORAL EQ 20MG BASE and 500MG
022511/002 VIMOVO ESOMEPRAZOLE MAGNESIUM; NAPROXEN TABLET, DELAYED RELEASE/ORAL EQ 20MG BASE and 375MG

Similar Active Ingredient

ApplId/ProductId Drug name Active ingredient Form Strenght
022511/001 VIMOVO ESOMEPRAZOLE MAGNESIUM; NAPROXEN TABLET, DELAYED RELEASE/ORAL EQ 20MG BASE and 500MG
022511/002 VIMOVO ESOMEPRAZOLE MAGNESIUM; NAPROXEN TABLET, DELAYED RELEASE/ORAL EQ 20MG BASE and 375MG
202461/001 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM ESOMEPRAZOLE MAGNESIUM; NAPROXEN TABLET, DELAYED RELEASE/ORAL EQ 20MG BASE and 375MG
202461/002 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM ESOMEPRAZOLE MAGNESIUM; NAPROXEN TABLET, DELAYED RELEASE/ORAL EQ 20MG BASE and 500MG

Ask a doctor

A licensed doctor will try to answer your question for free as quickly as possible. Free of charge during the beta period.

Related

Browse by letter
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

© Medications.li 2015-2017 - All rights reserved